Drug intelligence / Profile preview

anti-muc1 car-pnk cells

Development stage: Phase 2
Lead developer: PersonGen BioTherapeutics
Modality: CAR-NK Cells → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies
Administration: Intravenous, Intratumoral

Overview

Anti-MUC1 CAR-pNK cells are a novel immunotherapy approach that utilizes natural killer cells engineered with a chimeric antigen receptor targeting MUC1. This therapy is designed to treat MUC1-positive relapsed or refractory solid tumors. It works by enhancing the ability of natural killer cells to recognize and destroy cancer cells expressing the MUC1 antigen. Developed by PersonGen BioTherapeutics (Suzhou) Co., Ltd.

Other names: AntiMUC1 CAR-NK cellsAntiMUC-1 CAR-NK cellsAntiMUC 1 CAR-NK cellsAntimucin1 CAR-NK cell therapyAntimucin-1 CAR-NK cell therapyAntimucin 1 CAR-NK cell therapy

Targets

MUC1 (Mucin-1 Antigen)

Beyond the preview

Go deeper on anti-muc1 car-pnk cells.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on anti-muc1 car-pnk cells.

Explore the full profile